08.01.2013 - US-based Cubist Pharmaceuticals and British Heptares sealed a €7.2m license deal. Cubist pays to snatch a drug candidate for an undisclosed GPCR target.
The small spin-off Heptares Therapeutics from Welwyn Garden City north of London has landed a license deal with US biopharma Cubist Pharmaceuticals, Inc. Heptares’ area of expertise are G-protein coupled receptors (GPCR). Cubist will pay €4.2m up front and €3.1m in research funding plus undisclosed milestone payments and royalties. Heptares, in return, uses its proprietary platform technology to screen for drug candidates targeting an unnamed GPCR specified by Cubist. The deal also includes an option for a second target. Financial details covering that part of the collaboration have been predetermined – but will not be made public. Both parties agreed that the preclinical development will be carried out solely by Cubist.
Heptares was spun off from the Medical Research Council in 2007. The company engineers stabilised GPCRs (so-called STaRs), circumventing the problematic handling of the otherwise labile receptors. The UK firm entered biopharma main stage only last spring when it became eligible to receive payments potentially equalling €145m. Back then Irish Shire plc licensed a Heptares-discovered preclinical antagonist of the GPCR A2A (see photo) which could turn to a new CNS disorders medicine. Also AstraZeneca and Novartis belong to Heptares’ customers.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more